Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15882480 | 0.92 | MAP3K12 (1.00) | MAP3K12DLK1 | |
| SCHEMBL17388020 | 0.91 | MAP3K12 (1.00) | MAP3K12DLK1 | |
| SCHEMBL15890043 | 0.91 | MAP3K12 (1.00) | MAP3K12DLK1 | |
| SCHEMBL19921642 | 0.91 | MAP3K12 (1.00) | MAP3K12DLK1 | |
| SCHEMBL15882733 | 0.88 | MAP3K12 (1.00) | MAP3K12DLK1 | |
| SCHEMBL17407493 | 0.87 | MAP3K12 (0.86) | MAP3K12DLK1 | |
| SCHEMBL18662172 | 0.87 | MAP3K12 (0.77) | MAP3K12DLK1 | |
| SCHEMBL15882785 | 0.86 | MAP3K12 (1.00) | MAP3K12DLK1 | |
| SCHEMBL15882702 | 0.84 | MAP3K12 (1.00) | MAP3K12DLK1 | |
| SCHEMBL15882483 | 0.83 | MAP3K12 (1.00) | MAP3K12DLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | claimed |
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | claimed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | claimed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | claimed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | claimed |
| EP-2945938-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-11-25 | — | — | EP | claimed |
| WO-2014111496-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-24 | — | — | WO | claimed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | disclosed |
| EP-2945938-B1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2018-03-07 | — | — | EP | disclosed |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550777-B2 | 3-substituted pyrazoles and use as DLK inhibitors | GENENTECH, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014111496-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | PDXK, NLK, PDK3 | MAP3K12 128/4885DLK1 15/4885 |
| US-20170087137-A1 | 3-SUBSTITUTED PYRAZOLES AND USES THEREOF | PDXK, NLK, PDK3 | MAP3K12 235/4885DLK1 25/4885 |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | PDXK, NLK, PDK3 | MAP3K12 235/4885DLK1 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.